Cyprotex has extensive experience in DDI studies and is able to support full in vitro packages following US (FDA), European (EMA) and Japanese (PMDA) guidelines, as well as the new ICH M12 harmonised guidance. Initially, we work with you to design and plan your studies based on prior knowledge and data for your test article. Next, we implement the study in the laboratory according to the study design. Finally, we analyse, interpret and report on the data, and can assist with subsequent assessment of DDI risk.
